Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders

Abdel-Salam, 2015, The effect of cannabis on oxidative stress and neurodegeneration induced by intrastriatal rotenone injection in rats, Comparative Clinical Pathology, 24, 359, 10.1007/s00580-014-1907-9 Aguilera-Portillo, 2019, The pharmacological inhibition of fatty acid amide hydrolase prevents excitotoxic damage in the rat striatum: Possible involvement of CB1 receptors regulation, Molecular Neurobiology, 56, 844, 10.1007/s12035-018-1129-2 Ambrosi, 2014, A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease, Journal of Neural Transmission, 121, 849, 10.1007/s00702-013-1149-z Baek, 2018, Inhibition of microglia-derived oxidative stress by ciliary neurotrophic factor protects dopamine neurons in vivo from MPP+ neurotoxicity, International Journal of Molecular Sciences, 19, 3543, 10.3390/ijms19113543 Bai, 2017, Arachidonyl-2-Chloroethylamide alleviates cerebral ischemia injury through glycogen synthase kinase-3β-mediated mitochondrial biogenesis and functional improvement, Molecular Neurobiology, 54, 1240, 10.1007/s12035-016-9731-7 Benarroch, 2007, Endocannabinoids in basal ganglia circuits: Implications for Parkinson disease, Neurology, 69, 306, 10.1212/01.wnl.0000267407.79757.75 Berardelli, 1999, Pathophysiology of chorea and bradykinesia in Huntington's disease, Movement Disorders, 14, 398, 10.1002/1531-8257(199905)14:3<398::AID-MDS1003>3.0.CO;2-F Bilkei-Gorzo, 2018, Cannabinoid 1 receptor signaling on GABAergic neurons influences astrocytes in the ageing brain, PLoS One, 13, 10.1371/journal.pone.0202566 Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, British Journal of Pharmacology, 134, 845, 10.1038/sj.bjp.0704327 Bisogno, 2008, Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease, Neurochemistry International, 52, 307, 10.1016/j.neuint.2007.06.031 Blázquez, 2015, The CB1cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway, Cell Death and Differentiation, 22, 1618, 10.1038/cdd.2015.11 Blázquez, 2011, Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease, Brain, 134, 119, 10.1093/brain/awq278 Borrell-Pagès, 2006, Huntington's disease: From huntingtin function and dysfunction to therapeutic strategies, Cellular and Molecular Life Sciences, 63, 2642, 10.1007/s00018-006-6242-0 Bouchard, 2012, Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease, Journal of Neuroscience, 32, 18259, 10.1523/JNEUROSCI.4008-12.2012 Brusco, 2008, Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus, Synapse, 62, 944, 10.1002/syn.20569 Cabral, 2008, CB 2 receptors in the brain: Role in central immune function, British Journal of Pharmacology, 153, 240, 10.1038/sj.bjp.0707584 Cai, 2017, Activation of cannabinoid receptor 1 is involved in protection against mitochondrial dysfunction and cerebral ischaemic tolerance induced by isoflurane preconditioning, British Journal of Anaesthesia, 119, 1213, 10.1093/bja/aex267 Calabresi, 2014, Direct and indirect pathways of basal ganglia: A critical reappraisal, Nature Neuroscience, 17, 1022, 10.1038/nn.3743 Carroll, 2012, Δ9-tetrahydrocannabinol (Δ9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease, Neuropathology and Applied Neurobiology, 38, 535, 10.1111/j.1365-2990.2011.01248.x Castillo, 2010, The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2and adenosine receptors, Neurobiology of Disease, 37, 434, 10.1016/j.nbd.2009.10.023 Castillo, 2012, Endocannabinoid signaling and synaptic function, Neuron, 76, 70, 10.1016/j.neuron.2012.09.020 Cerri, 2014, Neuroprotective potential of adenosine A2Aand cannabinoid CB1receptor antagonists in an animal model of Parkinson disease, Journal of Neuropathology and Experimental Neurology, 73, 414, 10.1097/NEN.0000000000000064 Chagas, 2014, Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial, Journal of Psychopharmacology, 28, 1088, 10.1177/0269881114550355 Chen, 2000, Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism, The Journal of Pharmacology and Experimental Therapeutics, 293, 807 Chen, 2000, Human brain capillary endothelium: 2-Arachidonoglycerol (endocannabinoid) interacts with endothelin-1, Circulation Research, 87, 323, 10.1161/01.RES.87.4.323 Chiarlone, 2014, A restricted population of CB1 cannabinoid receptors with neuroprotective activity, Proceedings of the National Academy of Sciences of the United States of America, 111, 8257, 10.1073/pnas.1400988111 Chung, 2011, Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation, The Journal of Immunology, 187, 6508, 10.4049/jimmunol.1102435 Chung, 2016, CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease, Experimental and Molecular Medicine, 48, e205, 10.1038/emm.2015.100 Cristino, 2008, Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain, Neuroscience, 151, 955, 10.1016/j.neuroscience.2007.11.047 Dasilva, 2014, Anandamide activation of CB1 receptors increases spontaneous bursting and oscillatory activity in the thalamus, Neuroscience, 265, 72, 10.1016/j.neuroscience.2014.01.049 Demuth, 2006, Cannabinoid signalling, Life Sciences, 78, 549, 10.1016/j.lfs.2005.05.055 Denovan-Wright, 2000, Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice, Neuroscience, 98, 705, 10.1016/S0306-4522(00)00157-3 Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919 Díaz-Alonso, 2016, VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease, Scientific Reports, 6, 29789, 10.1038/srep29789 Domenici, 2006, Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission, Journal of Neuroscience, 26, 5794, 10.1523/JNEUROSCI.0372-06.2006 Dowie, 2009, Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease, Neuroscience, 163, 456, 10.1016/j.neuroscience.2009.06.014 Escamilla-Ramírez, 2017, URB597 and the cannabinoid WIN55,212-2 reduce behavioral and neurochemical deficits induced by MPTP in mice: Possible role of redox modulation and NMDA receptors, Neurotoxicity Research, 31, 532, 10.1007/s12640-016-9698-1 Esposito, 2006, Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement, Neuroscience Letters, 399, 91, 10.1016/j.neulet.2006.01.047 Esposito, 2007, Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression, British Journal of Pharmacology, 151, 1272, 10.1038/sj.bjp.0707337 Fernández-Ruiz, 2017, Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies, Vol. 593, 175, 10.1016/bs.mie.2017.06.021 Fernández-Ruiz, 2010, Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders, CNS Neuroscience & Therapeutics, 16, e72, 10.1111/j.1755-5949.2010.00144.x Fernández-Ruiz, 2011, Prospects for cannabinoid therapies in basal ganglia disorders, British Journal of Pharmacology, 163, 1365, 10.1111/j.1476-5381.2011.01365.x Fernández-Ruiz, 2008, Role of CB2receptors in neuroprotective effects of cannabinoids, Molecular and Cellular Endocrinology, 286, S91, 10.1016/j.mce.2008.01.001 Fernández-Ruiz, 2015, Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others, 233 Fernández-Ruiz, 2007, Cannabinoid CB2receptor: A new target for controlling neural cell survival?, Trends in Pharmacological Sciences, 28, 39, 10.1016/j.tips.2006.11.001 Fernández-Ruiz, 2013, Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?, British Journal of Clinical Pharmacology, 75, 323, 10.1111/j.1365-2125.2012.04341.x Fernández-Suárez, 2014, The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model, Neurobiology of Aging, 35, 2603, 10.1016/j.neurobiolaging.2014.05.021 Ferrer, 2003, Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias, European Journal of Neuroscience, 18, 1607, 10.1046/j.1460-9568.2003.02896.x Fidaleo, 2014, Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands, Current Medicinal Chemistry, 21, 2803, 10.2174/0929867321666140303143455 Fitzgerald, 2012, Cannabinoid modulation of the dopaminergic circuitry: Implications for limbic and striatal output, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38, 21, 10.1016/j.pnpbp.2011.12.004 Fowler, 2003, Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: Variability in response and involvement of arachidonic acid, Biochemical Pharmacology, 66, 757, 10.1016/S0006-2952(03)00392-7 Geldenhuys, 2013, Rationally designed multi-targeted agents against neurodegenerative diseases, Current Medicinal Chemistry, 20, 1662, 10.2174/09298673113209990112 Gerdeman, 2001, CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum, Journal of Neurophysiology, 85, 468, 10.1152/jn.2001.85.1.468 Gerfen, 2011, Modulation of striatal projection systems by dopamine, Annual Review of Neuroscience, 34, 441, 10.1146/annurev-neuro-061010-113641 Glass, 2000, The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease, Neuroscience, 97, 505, 10.1016/S0306-4522(00)00008-7 Glass, 2004, Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors, Neuroscience, 123, 207, 10.1016/S0306-4522(03)00595-5 Gong, 2006, Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain, Brain Research, 1071, 10, 10.1016/j.brainres.2005.11.035 Gulyas, 2004, Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala, European Journal of Neuroscience, 20, 441, 10.1111/j.1460-9568.2004.03428.x Hampson, 1998, Cannabidiol and (−) 9-tetrahydrocannabinol are neuroprotective antioxidants, Proceedings of the National Academy of Sciences of the United States of America, 95, 8268, 10.1073/pnas.95.14.8268 Hansen, 2002, Blockade of cannabinoid CB1receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity, Journal of Neurochemistry, 82, 154, 10.1046/j.1471-4159.2002.00961.x Hashimotodani, 2007, Presynaptic Monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the Hippocampus, Journal of Neuroscience, 27, 1211, 10.1523/JNEUROSCI.4159-06.2007 Hedreen, 1991, Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease, Neuroscience Letters, 133, 257, 10.1016/0304-3940(91)90583-F Heinsen, 1994, Cortical and striatal neurone number in Huntington's disease, Acta Neuropathologica, 88, 320, 10.1007/BF00310376 Hohmann, 2000, Localization of cannabinoid CB1receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study, Synapse, 37, 71, 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K Iuvone, 2009, Cannabidiol: A promising drug for neurodegenerative disorders?, CNS Neuroscience and Therapeutics, 15, 65, 10.1111/j.1755-5949.2008.00065.x Javed, 2016, Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of parkinson's disease, Frontiers in Neuroscience, 10, 321, 10.3389/fnins.2016.00321 Kallendrusch, 2013, The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion, Glia, 61, 1822, 10.1002/glia.22560 Karanian, 2007, Endocannabinoid enhancement protects against Kainic acid-induced seizures and associated brain damage, Journal of Pharmacology and Experimental Therapeutics, 322, 1059, 10.1124/jpet.107.120147 Katona, 2008, Endocannabinoid signaling as a synaptic circuit breaker in neurological disease, Nature Medicine, 14, 923, 10.1038/nm.f.1869 Kaur, 2017, Neuroinflammation—a major cause for striatal dopaminergic degeneration in Parkinson's disease, Journal of the Neurological Sciences, 381, 308, 10.1016/j.jns.2017.08.3251 Khaspekov, 2004, Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity, European Journal of Neuroscience, 19, 1691, 10.1111/j.1460-9568.2004.03285.x Kim, 2005, Transient receptor potential Vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro, Journal of Neuroscience, 25, 662, 10.1523/JNEUROSCI.4166-04.2005 Kofalvi, 2005, Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis, Journal of Neuroscience, 25, 2874, 10.1523/JNEUROSCI.4232-04.2005 Lanciego, 2011, Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis, Journal of Psychopharmacology, 25, 97, 10.1177/0269881110367732 Laprairie, 2014, The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients, Journal of Neuroimmunology, 267, 61, 10.1016/j.jneuroim.2013.12.008 Lastres-Becker, 2004, Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo, Neuroreport, 15, 2375, 10.1097/00001756-200410250-00015 Lastres-Becker, 2005, Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease, Neurobiology of Disease, 19, 96, 10.1016/j.nbd.2004.11.009 Leweke, 2012, Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Translational Psychiatry, 2, e94, 10.1038/tp.2012.15 Liu, 2014, Neuroprotective effects of trans-Caryophyllene against Kainic acid induced seizure activity and oxidative stress in mice, Neurochemical Research, 40, 118, 10.1007/s11064-014-1474-0 López, 2018, Cannabinoid CB2receptors in the mouse brain: Relevance for Alzheimer's disease, Journal of Neuroinflammation, 15, 158, 10.1186/s12974-018-1174-9 López-Sendón Moreno, 2016, A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease, Journal of Neurology, 263, 1390, 10.1007/s00415-016-8145-9 Lull, 2010, Microglial activation and chronic neurodegeneration, Neurotherapeutics, 7, 354, 10.1016/j.nurt.2010.05.014 Ma, 2015, Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions, Scientific Reports, 5, 12440, 10.1038/srep12440 MacDonald, 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72, 971, 10.1016/0092-8674(93)90585-E Mailleux, 1992, Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry, Neuroscience, 48, 655, 10.1016/0306-4522(92)90409-U Malek, 2015, Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures, Neural Plasticity, 2015, 130639, 10.1155/2015/130639 Marsicano, 2002, Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1, Journal of Neurochemistry, 80, 448, 10.1046/j.0022-3042.2001.00716.x Massano, 2012, Clinical approach to Parkinson's disease: Features, diagnosis, and principles of management, Cold Spring Harbor Perspectives in Medicine, 2, a008870, 10.1101/cshperspect.a008870 Maya-López, 2017, Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: Involvement of CB1 and NMDA receptors, American Journal of Translational Research, 9, 261 Maya-López, 2017, URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats, Biomedicine and Pharmacotherapy, 88, 745, 10.1016/j.biopha.2017.01.116 McCaw, 2004, Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice, European Journal of Biochemistry, 271, 4909, 10.1111/j.1432-1033.2004.04460.x Mechoulam, 2002, Cannabinoids and brain injury: Therapeutic implications, Trends in Molecular Medicine, 8, 58, 10.1016/S1471-4914(02)02276-1 Mezey, 2000, Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human, Proceedings of the National Academy of Sciences of the United States of America, 97, 3655, 10.1073/pnas.97.7.3655 Mievis, 2011, Worsening of Huntington disease phenotype in CB1 receptor knockout mice, Neurobiology of Disease, 42, 524, 10.1016/j.nbd.2011.03.006 Morera-Herreras, 2012, Endocannabinoid modulation of dopaminergic motor circuits, Frontiers in Pharmacology, 3, 110, 10.3389/fphar.2012.00110 Muñoz-Arenas, 2015, Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry, Synapse, 69, 103, 10.1002/syn.21796 Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0 Nadler, 1993, Blockade of45Ca2+influx through the N-methyl-d-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211, Brain Research, 622, 79, 10.1016/0006-8993(93)90804-V Naidoo, 2011, A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity, Journal of Molecular Neuroscience, 43, 493, 10.1007/s12031-010-9472-4 Navarrete, 2018, Cannabinoid CB1 and CB2 receptors, and Monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson's disease, Neurotherapeutics, 15, 1, 10.1007/s13311-018-0603-x Navarro, 2016, Targeting cannabinoid CB2receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders, Frontiers in Neuroscience, 10, 406 Naydenov, 2014, Genetic rescue of CB1receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice, Neurobiology of Disease, 71, 140, 10.1016/j.nbd.2014.08.009 Núñez, 2008, Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome, Neuroscience, 151, 104, 10.1016/j.neuroscience.2007.10.029 Nussbaum, 2003, Alzheimer's disease and Parkinson's disease, New England Journal of Medicine, 348, 1356, 10.1056/NEJM2003ra020003 O’Sullivan, 2016, An update on PPAR activation by cannabinoids, British Journal of Pharmacology, 173, 1899, 10.1111/bph.13497 Oh, 2010, Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-κB activation in BV2 murine microglial cells, Neuroscience Letters, 474, 148, 10.1016/j.neulet.2010.03.026 Ojha, 2016, β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease, Molecular and Cellular Biochemistry, 418, 59, 10.1007/s11010-016-2733-y Onaivi, 2006, Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain, Annals of the New York Academy of Sciences, 1074, 514, 10.1196/annals.1369.052 Ouchi, 2005, Microglial activation and dopamine terminal loss in early Parkinson's disease, Annals of Neurology, 57, 168, 10.1002/ana.20338 Palazuelos, 2009, Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity, Brain, 132, 3152, 10.1093/brain/awp239 Pazos, 2013, Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1Aand CB2 receptors, Neuropharmacology, 71, 282, 10.1016/j.neuropharm.2013.03.027 Pelição, 2016, URB597 inhibits oxidative stress induced by alcohol binging in the prefrontal cortex of adolescent rats, Neuroscience Letters, 624, 17, 10.1016/j.neulet.2016.04.068 Pintor, 2006, The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum, Neuropharmacology, 51, 1004, 10.1016/j.neuropharm.2006.06.013 Piomelli, 2003, The molecular logic of endocannabinoid signalling, Nature Reviews Neuroscience, 4, 873, 10.1038/nrn1247 Poewe, 2010, The clinical progression of Parkinson's disease, Parkinsonism & Related Disorders, 15, S28 Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, European Journal of Neuroscience, 29, 2177, 10.1111/j.1460-9568.2009.06764.x Ramirez, 2005, Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation, Journal of Neuroscience, 25, 1904, 10.1523/JNEUROSCI.4540-04.2005 Ramsey, 2014, A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets, Experimental Neurology, 256, 126, 10.1016/j.expneurol.2013.05.014 Rangel-López, 2015, Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain, Neuroscience, 285, 97, 10.1016/j.neuroscience.2014.11.016 Reiner, 1988, Differential loss of striatal projection neurons in Huntington disease, Proceedings of the National Academy of Sciences of the United States of America, 85, 5733, 10.1073/pnas.85.15.5733 Romero, 2002, The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects, Pharmacology and Therapeutics, 95, 137, 10.1016/S0163-7258(02)00253-X Saft, 2018, Cannabinoids for treatment of dystonia in Huntington's disease, Journal of Huntington's Disease, 7, 167, 10.3233/JHD-170283 Sagredo, 2007, Cannabinoids and neuroprotection in basal ganglia disorders, Molecular Neurobiology, 36, 82, 10.1007/s12035-007-0004-3 Sagredo, 2009, Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease, Glia, 57, 1154, 10.1002/glia.20838 Sagredo, 2011, Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease, Journal of Neuroscience Research, 89, 1509, 10.1002/jnr.22682 Schapira, 2008, Mitochondria in the aetiology and pathogenesis of Parkinson's disease, The Lancet Neurology, 7, 97, 10.1016/S1474-4422(07)70327-7 Schapira, 2014, Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: Future therapeutic perspectives, The Lancet, 384, 545, 10.1016/S0140-6736(14)61010-2 Scuderi, 2014, Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement, Phytotherapy Research, 28, 1007, 10.1002/ptr.5095 Serpa, 2015, Combined neuroprotective action of adenosine A1and cannabinoid CB1receptors against NMDA-induced excitotoxicity in the hippocampus, Neurochemistry International, 87, 106, 10.1016/j.neuint.2015.06.005 Sheng, 2009, WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: Involvement of p38 MAP kinase, Journal of Neuroimmune Pharmacology, 4, 244, 10.1007/s11481-009-9147-5 Sierra, 2015, Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: Changes following experimental parkinsonism, Brain Structure and Function, 220, 2721, 10.1007/s00429-014-0823-8 Smith, 2000, Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice, The Journal of Pharmacology and Experimental Therapeutics, 293, 136 Solinas, 2006, Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Journal of Neurochemistry, 98, 408, 10.1111/j.1471-4159.2006.03880.x Starowicz, 2007, Biochemistry and pharmacology of endovanilloids, Pharmacology and Therapeutics, 114, 13, 10.1016/j.pharmthera.2007.01.005 Sugiura, 2006, Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, Progress in Lipid Research, 45, 405, 10.1016/j.plipres.2006.03.003 Sun, 2017, Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons, Redox Biology, 11, 577, 10.1016/j.redox.2016.12.029 Takahashi, 2006, The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus, Neuroscience, 139, 795, 10.1016/j.neuroscience.2006.01.024 Tanimura, 2010, The endocannabinoid 2-Arachidonoylglycerol produced by diacylglycerol lipase α mediates retrograde suppression of synaptic transmission, Neuron, 65, 320, 10.1016/j.neuron.2010.01.021 Teismann, 2004, Cellular pathology of Parkinson's disease: Astrocytes, microglia and inflammation, Cell and Tissue Research, 318, 149, 10.1007/s00441-004-0944-0 Thomas, 2009, Parkinson's disease: From molecular pathways in disease to therapeutic approaches, Antioxidants & Redox Signaling, 11, 2077, 10.1089/ars.2009.2697 van der Stelt, 2003, The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders, European Journal of Pharmacology, 480, 133, 10.1016/j.ejphar.2003.08.101 van der Stelt, 2001, Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against Ouabain-induced in vivo excitotoxicity, The Journal of Neuroscience, 21, 6475, 10.1523/JNEUROSCI.21-17-06475.2001 van der Stelt, 2002, Acute neuronal injury, excitotoxicity, and the endocannabinoid system, Molecular Neurobiology, 26, 317, 10.1385/MN:26:2-3:317 Van Laere, 2010, Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 51, 1413, 10.2967/jnumed.110.077156 Van Sickle, 2005, Neuroscience: Identification and functional characterization of brainstem cannabinoid CB2 receptors, Science, 310, 329, 10.1126/science.1115740 Varvel, 2006, Fatty acid amide hydrolase (−/−) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task, The Journal of Pharmacology and Experimental Therapeutics, 317, 251, 10.1124/jpet.105.095059 Veldhuis, 2003, Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: Role of vanilloid receptors and lipoxygenases, The Journal of Neuroscience, 23, 4127, 10.1523/JNEUROSCI.23-10-04127.2003 Vrechi, 2018, Cannabinoid receptor type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling, Neurotoxicity Research, 33, 846, 10.1007/s12640-017-9839-1 Walter, 2003, Nonpsychotropic cannabinoid receptors regulate microglial cell migration, The Journal of Neuroscience, 23, 1398, 10.1523/JNEUROSCI.23-04-01398.2003 Yang, 2014, Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy, Free Radical Biology and Medicine, 68, 260, 10.1016/j.freeradbiomed.2013.12.026 Zeissler, 2016, Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis, Oncotarget, 7, 46603, 10.18632/oncotarget.10314 Zhang, 2014, Cannabinoid CB 2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice, Proceedings of the National Academy of Sciences, 111, E5007, 10.1073/pnas.1413210111